---
layout: paper
title: "Scalable whole-exome sequencing of cell-free DNA
reveals high concordance with metastatic tumors"
image: /images/papers/Adalsteinsson-ulpwgs.png
authors: Viktor A. Adalsteinsson, Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Daniel G. Stover, Heather A. Parsons, Gregory Gydush, Sarah C. Reed, Denisse Rotem, Justin Rhoades, Denis Loginov, Dimitri Livitz, Daniel Rosebrock, Ignaty Leshchiner, Jaegil Kim, Chip Stewart, Mara Rosenberg, Joshua M. Francis, Cheng-Zhong Zhang, Ofir Cohen, Coyin Oh, Huiming Ding, Paz Polak, Max Lloyd, Sairah Mahmud, Karla Helvie, Margaret S. Merrill, Rebecca A. Santiago, Edward P. O’Connor, Seong H. Jeong, Rachel Leeson, Rachel M. Barry, Joseph F. Kramkowski, Zhenwei Zhang, Laura Polacek, Jens Lohr, Molly Schleicher, Emily Lipscomb, Andrea Saltzman, Nelly M. Oliver, Lori Marini, Adrienne G. Waks, Lauren C. Harshman, Sara M. Tolaney, Eliezer M. Van Allen, Eric P. Winer, Nancy U. Lin, Mari Nakabayashi, Mary-Ellen Taplin, Cory M. Johannessen, Levi A. Garraway, Todd R. Golub, Jesse S. Boehm, Nikhil Wagle, Gad Getz, J. Christopher Love, Matthew Meyerson.
year: 2017
authorshort: Adalsteinsson VA*, <strong>Ha G*</strong>, Freeman SS, et al.
journal: Nat Commun.
vol: 8(1)
pdf: /pdfs/papers/adalsteinsson-ha-2017-natcomms-cfdna.pdf
doi: 10.1038/s41467-017-00965-y
github: https://github.com/broadinstitute/ichorCNA
---

# Abstract

Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling of
tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies is
uncertain. Here we report ichorCNA, software that quantifies tumor content in cfDNA from
0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations.
We apply ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or
breast cancers. In the earliest tested sample for each patient, 34% of patients have ≥10%
tumor-derived cfDNA, sufficient for standard coverage whole-exome sequencing. Using
whole-exome sequencing, we validate the concordance of clonal somatic mutations (88%),
copy number alterations (80%), mutational signatures, and neoantigens between cfDNA and
matched tumor biopsies from 41 patients with ≥10% cfDNA tumor content. In summary, we
provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing its
applicability to many patients, and demonstrate high concordance of cfDNA and metastatic
tumor whole-exome sequencing.

![Adalsteinsson V, Ha G, Freeman S, et al. (2017) Nat Commun.](/images/papers/Adalsteinsson-workflow.png)
